Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (32)

II-01Noha Abdelgawad

Population pharmacokinetics of pyrazinamide in hospitalised TB patients with HIV versus TB outpatients

II-02Mahmoud Abdelwahab

Population Pharmacokinetic/Pharmacodynamic Modelling of Clofazimine Effects on QTcF in South African tuberculosis patients

II-03Leticia Arrington

Evaluation of IRT-derived disease severity as a predictor of clinical success in critically ill patients with severe antibiotic resistant infections

II-04Fauke Assmus

Population pharmacokinetics of benznidazole as monotherapy and in combination with fosravuconazole in adult patients with chronic Chagas disease (BENDITA study)

II-05Rami Ayoun Alsoud

Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data

II-06Irina Bondareva

Population pharmacokinetics of meropenem in adult intensive care unit (ICU) patients estimated from therapeutic drug monitoring data (TDM) data

II-07Unai Caballero

Pharmacokinetic/pharmacodynamic modelling and simulation of the in vitro activity of isavuconazole and echinocandin combination against Candida auris.

II-08Lu Chen

Pharmacokinetics of fluconazole in obese and non-obese adults upon a semi-simultaneous oral and IV study design

II-09Palang Chotsiri

Piperaquine pharmacokinetics during intermittent preventive treatment for malaria in pregnancy

II-10Selma El Messaoudi

A mechanistic model to characterize the long-term dynamic of HBV markers in Lamivudine and PEG-IFNa treated patients

II-11Teresa Garcia

Non-linear binding model of total daptomycin in patients with normal and impaired renal function

II-12Kamunkhwala Gausi

Pharmacokinetics of high dose isoniazid among individuals with multidrug-resistant tuberculosis

II-13Victória Etges Helfer

Population pharmacokinetic modeling of ceftaroline characterizing tissue distribution following different ceftaroline fosamil infusion regimens to volunteers undergoing muscle and subcutaneous tissue microdialysis

II-14Richard Höglund

Pharmacokinetics and pharmacodynamics of ivermectin and its metabolites

II-15Aida Kawuma

Rifabutin changes dolutegravir’s half-life but not area under the curve when co-administered

II-16Guillaume Lingas

Lassa viral dynamics in macaques treated with favipiravir or ribavirin

II-17Feiyan Liu

Modeling inflammatory biomarker dynamics in human LPS challenge studies using delay differential equations

II-18Nele Mueller-Plock

Predicting RSV efficacy for moderate and tropical climates considering seasonal differences in RSV force-of-infection – Application of an MBMA and clinical trial simulation framework to support MK-1654 decision making

II-19Anh Duc Pham

Modelling rate and extent of resistance development against colistin in Klebsiella pneumoniae

II-20Viktor Rognås

Turn-over model characterizing effect of colistin on serum-creatinine in critically ill patients

II-21Federico Romano

Model-based extrapolation of the early bacterial activity (EBA) of bedaquiline-combination regimens for the treatment of pulmonary tuberculosis

II-22Louis Sandra

A target-mediated drug disposition model describing plasma and liver pharmacokinetics of JNJ-73763989 in AAV-HBV mice

II-23Hiie Soeorg

Prediction of C-reactive protein dynamics during meropenem treatment in very-low-birth-weight neonates with late-onset sepsis or pneumonia

II-24Jesper Sundell

Model-based characterization of drug-drug interaction between isoniazid and rifampicin

II-25Lénaïg Tanneau

Population pharmacokinetics of delamanid and its main metabolite DM-6705 in patients with multidrug resistant tuberculosis

II-26David Uster

Evaluation of four distinct weighting schemes in a model averaging and selection approach in model-informed precision dosing of continuously infused vancomycin

II-27Stijn van Beek

Modeling the relationship between plasma and intracellular pharmacokinetics of bedaquiline and its metabolite M2 in South African patients with rifampicin-resistant tuberculosis

II-28Luka Verrest

Pharmacokinetic-pharmacodynamic modelling of Leishmania blood parasite kinetics in visceral leishmaniasis patients

II-29Qianwen Wang

Determination of risk factors for time to culture conversion in tuberculosis patients receiving novel regimen

II-30Thanaporn Wattanakul

Semi-mechanistic Pharmacokinetic and Pharmacodynamic Modeling of Piperaquine in a Volunteer Infection Study with Plasmodium falciparum Blood-Stage Malaria

II-31Justin Wilkins

PK/PD modelling of M5717 in malaria

II-32Tan Zhang

A population pharmacokinetic analysis to evaluate the impact of body weight, renal function, and patient status on vancomycin pharmacokinetics